{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:30:20Z","timestamp":1793374220275,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2023YFC2706304"],"award-info":[{"award-number":["2023YFC2706304"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2023YFC2706305"],"award-info":[{"award-number":["2023YFC2706305"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2016YFC0901502"],"award-info":[{"award-number":["2016YFC0901502"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81471329"],"award-info":[{"award-number":["81471329"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Sirolimus is increasingly utilized in treating diseases associated with mTOR pathway overactivation. Despite its potential, the lack of evidence regarding its long-term safety across all age groups, particularly in pediatric patients, has limited its further application. This study aims to assess the long-term safety of sirolimus, with a specific focus on its impact on growth patterns in pediatric patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This pooled analysis inlcudes two prospective cohort studies spanning 10 years, including 1,738 participants (aged 5 days to 69 years) diagnosed with tuberous sclerosis and\/or lymphangioleiomyomatosis. All participants were mTOR inhibitor-naive and received 1\u00a0mg\/m\u00b2\/day of sirolimus, with dose adjustments during a two-week titration period to maintain trough blood concentrations between 5 and 10 ng\/ml (maximum dose 2\u00a0mg). Indicators of physical growth, hematopoietic, liver, renal function, and blood lipid levels were all primary outcomes and were analyzed. The adverse events and related management were also recorded.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sirolimus administration did not lead to deviations from normal growth ranges, but higher doses exhibited a positive association with Z-scores exceeding 2 SD in height, weight, and BMI. Transient elevations in red blood cell and white blood cell counts, along with hyperlipidemia, were primarily observed within the first year of treatment. Other measured parameters remained largely unchanged, displaying only weak correlations with drug use. Stomatitis is the most common adverse event (920\/1738, 52.9%). In adult females, menstrual disorders were observed in 48.5% (112\/217).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Sirolimus\u2019s long-term administration is not associated with adverse effects on children\u2019s physical growth pattern, nor significant alterations in hematopoietic, liver, renal function, or lipid levels. A potential dose-dependent influence on growth merits further exploration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Pediatric patients: Chinese clinical trial registry, No. ChiCTR-OOB-15,006,535. Adult patients: ClinicalTrials, No. NCT03193892.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-024-03243-5","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T08:01:51Z","timestamp":1723708911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Long-term safety and influence on growth in patients receiving sirolimus: a pooled analysis"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8141-0858","authenticated-orcid":false,"given":"Yang-Yang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-9378","authenticated-orcid":false,"given":"Li-Ping","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Shuai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Lun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Yu","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Fang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Dun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Mei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Lu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Fen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"issue":"10126","key":"3243_CR1","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","volume":"391","author":"Z-W Lai","year":"2018","unstructured":"Lai Z-W, Kelly R, Winans T, Marchena I, Shadakshari A, Yu J, et al. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial. Lancet. 2018;391(10126):1186\u201396.","journal-title":"Lancet"},{"issue":"12","key":"3243_CR2","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1093\/annonc\/mdx536","volume":"28","author":"J Martin-Broto","year":"2017","unstructured":"Martin-Broto J, Redondo A, Valverde C, Vaz MA, Mora J, Del Garcia X, et al. Gemcitabine plus Sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). Annals Oncology: Official J Eur Soc Med Oncol. 2017;28(12):2994\u20139.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"20","key":"3243_CR3","first-page":"8140","volume":"14","author":"MV Blagosklonny","year":"2022","unstructured":"Blagosklonny MV. Rapamycin treatment early in life reprograms aging: hyperfunction theory and clinical practice. Aging. 2022;14(20):8140\u20139.","journal-title":"Aging"},{"issue":"7432","key":"3243_CR4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature11861","volume":"493","author":"SC Johnson","year":"2013","unstructured":"Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature. 2013;493(7432):338\u201345.","journal-title":"Nature"},{"issue":"6","key":"3243_CR5","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;168(6):960\u201376.","journal-title":"Cell"},{"issue":"10","key":"3243_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.3324\/haematol.2017.163675","volume":"102","author":"X Feng","year":"2017","unstructured":"Feng X, Lin Z, Sun W, Hollinger MK, Desierto MJ, Keyvanfar K, et al. Rapamycin is highly effective in murine models of immune-mediated bone marrow failure. Haematologica. 2017;102(10):1691\u2013703.","journal-title":"Haematologica"},{"issue":"7","key":"3243_CR7","first-page":"813","volume":"42","author":"LS Nguyen","year":"2019","unstructured":"Nguyen LS, Vautier M, Allenbach Y, Zahr N, Benveniste O, Funck-Brentano C, Salem JE. Sirolimus and mTOR inhibitors: a review of Side effects and Specific Management in Solid Organ Transplantation. Drug Saf. 2019;42(7):813\u201325.","journal-title":"Drug Saf"},{"issue":"2","key":"3243_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1432-2277.2009.00969.x","volume":"23","author":"M Molinari","year":"2010","unstructured":"Molinari M, Berman K, Meeberg G, Shapiro JA, Bigam D, Trotter JF, Kneteman N. Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients. Transpl Int. 2010;23(2):155\u201368.","journal-title":"Transpl Int"},{"issue":"17","key":"3243_CR9","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","volume":"364","author":"FX McCormack","year":"2011","unstructured":"McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595\u2013606.","journal-title":"N Engl J Med"},{"issue":"10","key":"3243_CR10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1212\/WNL.0000000000003077","volume":"87","author":"IE Overwater","year":"2016","unstructured":"Overwater IE, Rietman AB, Bindels-de Heus K, Looman CW, Rizopoulos D, Sibindi TM, et al. Sirolimus for epilepsy in children with tuberous sclerosis complex: a randomized controlled trial. Neurology. 2016;87(10):1011\u20138.","journal-title":"Neurology"},{"issue":"2","key":"3243_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1399-0012.2007.00756.x","volume":"22","author":"EL Sampaio","year":"2008","unstructured":"Sampaio EL, Pinheiro-Machado PG, Garcia R, Felipe CR, Park SI, Casarini DE, et al. Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen. Clin Transpl. 2008;22(2):141\u20139.","journal-title":"Clin Transpl"},{"issue":"9639","key":"3243_CR12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","volume":"372","author":"P Curatolo","year":"2008","unstructured":"Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372(9639):657\u201368.","journal-title":"Lancet"},{"key":"3243_CR13","doi-asserted-by":"crossref","unstructured":"Dun S, Wang YY, Wan L, Wang QH, Lu Q, Yang XY et al. Sirolimus can promote the disappearance of renal angiomyolipoma associated with tuberous sclerosis complex: a prospective cohort study. World J Pediatr. 2023.","DOI":"10.1007\/s12519-023-00751-5"},{"issue":"2","key":"3243_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for Angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358(2):140\u201351.","journal-title":"N Engl J Med"},{"key":"3243_CR15","doi-asserted-by":"crossref","unstructured":"Chen XQ, Wang YY, Zhang MN, Lu Q, Pang LY, Liu LY et al. Sirolimus Can Increase the Disappearance Rate of Cardiac Rhabdomyomas Associated with Tuberous Sclerosis: A Prospective Cohort and Self-Controlled Case Series Study. J Pediatr. 2021;233:150-5.e4.","DOI":"10.1016\/j.jpeds.2021.02.040"},{"key":"3243_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.seizure.2020.03.018","volume":"79","author":"W He","year":"2020","unstructured":"He W, Chen J, Wang YY, Zhang MN, Qian L, Wang QH, et al. Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: a prospective cohort study. Seizure. 2020;79:20\u20136.","journal-title":"Seizure"},{"issue":"10","key":"3243_CR17","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s00467-009-1215-9","volume":"24","author":"GA Rangel","year":"2009","unstructured":"Rangel GA, Ariceta G. Growth failure associated with sirolimus: case report. Pediatr Nephrol. 2009;24(10):2047\u201350.","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"3243_CR18","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00467-011-1811-3","volume":"26","author":"D Gonz\u00e1lez","year":"2011","unstructured":"Gonz\u00e1lez D, Garc\u00eda CD, Az\u00f3car M, Waller S, Alonso A, Ariceta G, et al. Growth of kidney-transplanted pediatric patients treated with sirolimus. Pediatr Nephrol. 2011;26(6):961\u20136.","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"3243_CR19","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1093\/ckj\/sfaa262","volume":"14","author":"MG Naik","year":"2020","unstructured":"Naik MG, Arns W, Budde K, Diekmann F, Eitner F, Gwinner W, et al. Sirolimus in renal transplant recipients with malignancies in Germany. Clin Kidney J. 2020;14(9):2047\u201358.","journal-title":"Clin Kidney J"},{"issue":"4","key":"3243_CR20","doi-asserted-by":"publisher","first-page":"151442","DOI":"10.1016\/j.semnephrol.2023.151442","volume":"43","author":"D Puliyanda","year":"2023","unstructured":"Puliyanda D, Barday Z, Barday Z, Freedman A, Todo T, Chen AKC, Davidson B. Children are not small adults: similarities and differences in renal transplantation between adults and pediatrics. Semin Nephrol. 2023;43(4):151442.","journal-title":"Semin Nephrol"},{"issue":"8","key":"3243_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2165\/00003088-200140080-00002","volume":"40","author":"K Mahalati","year":"2001","unstructured":"Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet. 2001;40(8):573\u201385.","journal-title":"Clin Pharmacokinet"},{"key":"3243_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.exger.2017.12.026","volume":"105","author":"E Kraig","year":"2018","unstructured":"Kraig E, Linehan LA, Liang H, Romo TQ, Liu Q, Wu Y, et al. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: immunological, physical performance, and cognitive effects. Exp Gerontol. 2018;105:53\u201369.","journal-title":"Exp Gerontol"},{"issue":"3","key":"3243_CR23","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.transproceed.2006.01.044","volume":"38","author":"S Merkel","year":"2006","unstructured":"Merkel S, Mogilevskaja N, Mengel M, Haller H, Schwarz A. Side effects of sirolimus. Transpl Proc. 2006;38(3):714\u20135.","journal-title":"Transpl Proc"},{"issue":"1","key":"3243_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11523-017-0539-9","volume":"13","author":"J Martin-Liberal","year":"2018","unstructured":"Martin-Liberal J, L\u00f3pez-Pousa A, Mart\u00ednez-Trufero J, Mart\u00edn-Broto J, Cubedo R, Lavernia J, et al. Phase II study of Gemcitabine Plus Sirolimus in previously treated patients with Advanced Soft-tissue sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study. Target Oncol. 2018;13(1):81\u20137.","journal-title":"Target Oncol"},{"issue":"3","key":"3243_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/bjh.14057","volume":"174","author":"J Wang","year":"2016","unstructured":"Wang J, Tran J, Wang H, Guo C, Harro D, Campbell AD, Eitzman DT. mTOR inhibition improves anaemia and reduces organ damage in a murine model of sickle cell disease. Br J Haematol. 2016;174(3):461\u20139.","journal-title":"Br J Haematol"},{"issue":"11","key":"3243_CR26","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1002\/stem.3268","volume":"38","author":"Q Liu","year":"2020","unstructured":"Liu Q, Luo L, Ren C, Zou M, Yang S, Cai B, et al. The opposing roles of the mTOR signaling pathway in different phases of human umbilical cord blood-derived CD34(+) cell erythropoiesis. Stem Cells. 2020;38(11):1492\u2013505.","journal-title":"Stem Cells"},{"issue":"12","key":"3243_CR27","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1038\/nm.2984","volume":"18","author":"J Huang","year":"2012","unstructured":"Huang J, Nguyen-McCarty M, Hexner EO, Danet-Desnoyers G, Klein PS. Maintenance of hematopoietic stem cells through regulation of wnt and mTOR pathways. Nat Med. 2012;18(12):1778\u201385.","journal-title":"Nat Med"},{"issue":"5","key":"3243_CR28","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/ndt\/gfp674","volume":"25","author":"S Sofroniadou","year":"2010","unstructured":"Sofroniadou S, Kassimatis T, Goldsmith D. Anaemia, microcytosis and sirolimus\u2013is iron the missing link? Nephrol Dial Transpl. 2010;25(5):1667\u201375.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"3243_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","volume":"127","author":"KL Bride","year":"2016","unstructured":"Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, et al. Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016;127(1):17\u201328.","journal-title":"Blood"},{"issue":"5","key":"3243_CR30","first-page":"753","volume":"20","author":"M Sattler","year":"1992","unstructured":"Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992;20(5):753\u201361.","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"3243_CR31","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1345\/aph.1E165","volume":"38","author":"GW Neff","year":"2004","unstructured":"Neff GW, Ruiz P, Madariaga JR, Nishida S, Montalbano M, Meyer D, et al. Sirolimus-associated hepatotoxicity in liver transplantation. Ann Pharmacother. 2004;38(10):1593\u20136.","journal-title":"Ann Pharmacother"},{"key":"3243_CR32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.cca.2019.01.001","volume":"490","author":"J Liu","year":"2019","unstructured":"Liu J, Dai Y, Lee Y, Yuan E, Wang Q, Wang L, Su Y. Pediatric reference intervals of liver and renal function tests from birth to adolescence in Chinese children as performed on the Olympus AU5400. Clin Chim Acta. 2019;490:142\u20136.","journal-title":"Clin Chim Acta"},{"issue":"7","key":"3243_CR33","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1161\/01.CIR.65.7.1290","volume":"65","author":"SL Connor","year":"1982","unstructured":"Connor SL, Connor WE, Sexton G, Calvin L, Bacon S. The effects of age, body wight and family relationships on plasma lipoproteins and lipids in men, women and children of randomly selected families. Circulation. 1982;65(7):1290\u20138.","journal-title":"Circulation"},{"issue":"8","key":"3243_CR34","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/sj.ki.5002112","volume":"71","author":"S Huber","year":"2007","unstructured":"Huber S, Bruns CJ, Schmid G, Hermann PC, Conrad C, Niess H, et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int. 2007;71(8):771\u20137.","journal-title":"Kidney Int"},{"issue":"11","key":"3243_CR35","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1056\/NEJMc1113145","volume":"366","author":"M Braun","year":"2012","unstructured":"Braun M, Young J, Reiner CS, Poster D, W\u00fcthrich RP, Serra AL. Ovarian toxicity from sirolimus. N Engl J Med. 2012;366(11):1062\u20134.","journal-title":"N Engl J Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03243-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03243-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03243-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T08:04:04Z","timestamp":1723709044000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03243-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3243"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03243-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,15]]},"assertion":[{"value":"11 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of Chinese PLA General Hospital (No. S2013-028-01) and the Ethics Committee of Peking Union Medical College Hospital (PUMCH) approved this study (JS-1323). Consent from all patients included is available.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest relevant to this article to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"299"}}